NASDAQ NMS - GLOBAL MARKET · PMN
+10.35% · +$1.38 · Vol 27.7K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
ProMIS Neurosciences Inc

ProMIS Neurosciences Inc

Biotechnology
$14.71
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
PMN
ProMIS Neurosciences Inc
Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

56/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PMN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PMN catalysts
About ProMIS Neurosciences Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2005
Employees
11
Country
CA

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$13.53
Day high
$14.71
Day low
$13.33
Previous close
$13.33
52W high
$24.79
-40.66% from high
52W low
$6.76
44% of range
Market cap
$119.5M
EPS
$-1.4000
Beta
1.04
Shares out
9M
Volume
27.7K
0.18× rel vol
Avg volume
149.9K
VWAP
$13.95
Price history computed in-house
1W
+7.22%
1M
+3.08%
3M
+49.64%
1Y
+4.33%
YTD
+115.53%
SMA 50 $12.21 · above
SMA 200 $12.03 · above
52W position 44%

PMN overview

Veridion Score
56
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PMN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PMN Form 4 filings
Public disclosures

Congress activity in PMN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PMN in the cached public ledger.

Federal contracts

PMN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PMN in this window.
Lobbying spend

PMN lobbying filings, year to date.

Registered lobbying filings matched to ProMIS Neurosciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PMN in this window.
Loading news for PMN
Analyst ratings
Sovereign unlock shows live analyst consensus for PMN.
Options
Sovereign unlock shows live options positioning for PMN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.